A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors

Category Primary study
JournalMolecular Cancer Therapeutics
Year 2013
This article has no abstract
Epistemonikos ID: fee7f61993cf210d4d26b8f1a9d2bf8ea80ae079
First added on: Feb 05, 2025